Result of AGM

RNS Number : 2998H

Advanced Oncotherapy PLC

02 August 2021

 

The following amendment has been made to the 'Result of AGM' announcement released on Friday, 30 July 2021 at 16:58 under RNS No 1382H.

The announcement has now been updated to reflect the correct number of total votes for 'Resolution 8. To re-appoint Dr Michael Sinclair as a Director of the Company' of 160,443,006.

All other details remain unchanged.

The full amended text is shown below.

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Result of AGM

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at the Annual General Meeting held earlier today, all resolutions were passed. The results of the proxy voting for the AGM are set out below:

Resolution	Total votes For1	% of votes cast2	Total Votes Against	% of votes cast2	Votes Withheld3
1. To receive the audited financial statements and the Auditor's and Directors' reports for the year ended 31st December 2020	145,271,844	90.51	15,225,620	9.49	3,989
2. To re-appoint Michael Bradfield as a Director of the Company	145,214,749	90.48	15,285,644	9.52	1,060
3. To re-appoint Hans von Celsing as a Director of the Company	145,218,006	90.48	15,282,387	9.52	1,060
4. To re-appoint Lori Cross as a Director of the Company	160,443,006	99.96	57,387	0.04	1,060
5. To re-appoint Prof. Steve Myers as a Director of the Company	160,443,006	99.96	57,387	0.04	1,060
6. To re-appoint Dr Nick Plowman as a Director of the Company	160,443,006	99.96	57,387	0.04	1,060
7. To re-appoint Nicolas Serandour as a Director of the Company	160,439,749	99.96	60,644	0.04	1,060
8. To re-appoint Dr Michael Sinclair as a Director of the Company	160,443,006	99.96	67,387	0.04	1,060
9. To re-appoint Dr Enrico Vanni as a Director of the Company	145,218,006	90.48	15,282,387	9.52	1,060
10. To re-appoint Renhua Zhang as a Director of the Company	160,444,317	99.97	56,076	0.03	1,060
11. To re-appoint RPG Crouch Chapman LLP as Auditors of the Company	160,499,063	99.99	500	0.01	1,890
12. To authorise the Directors to determine the remuneration of the Auditors	160,493,344	99.99	6,099	0.01	2,010
13. Authority to allot shares	160,485,344	99.99	6,929	0.01	9,180
14. Authority to disapply pre-emption rights	145,260,344	90.51	15,231,929	9.49	9,180

Notes

1.  Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution

2.  Percentage of votes cast excludes Votes Withheld

3.  Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution

- ENDS -

Notes for editors

Advanced Oncotherapy plc	www.avoplc.com
Dr. Michael Sinclair, Executive Chairman	Tel: [phone]
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad and Joint Broker)
Nick Athanas / Liz Kirchner (Corporate Finance) Amrit Nahal / Matt Butlin (Sales and Corporate Broking)	Tel: [phone]
SI Capital Ltd (Joint Broker)
Nick Emerson	Tel: [phone]
Jon Levinson	Tel: [phone]
FTI Consulting (Financial PR & IR)	[e-mail]
Simon Conway / Rob Winder	Tel: [phone]

About Advanced Oncotherapy Plc

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

RAGSSSFLEEFSEDA